Literature DB >> 1546845

The role of cyclooxygenase products in lung injury induced by tumor necrosis factor in sheep.

A P Wheeler1, W D Hardie, G R Bernard.   

Abstract

Tumor necrosis factor-alpha (TNF alpha) has been proposed as a mediator of endotoxin-induced lung injury. When given to sheep, TNF alpha mimics endotoxin (LPS) causing hypoxemia, pulmonary hypertension, leukopenia, reduced dynamic compliance (Cdyn), increased resistance to airflow (RL), exudation of lung lymph, and enhanced airway reactivity. TNF alpha also induces rapid release of thromboxane A2 (TxA2), prostaglandin E2 (PGE2), and prostacyclin (PGI2). We hypothesized that the inflammatory effects of TNF alpha are due at least in part to cyclooxygenase products, and therefore cyclooxygenase inhibition would have similar effects on TNF alpha-induced lung injury as has previously been demonstrated for LPS-induced lung damage. Using awake sheep with chronic lung lymph fistulas, we measured Cdyn, RL, and FRC using a whole-body plethysmograph. Pulmonary artery (Ppa), left atrial (PLA), and systemic arterial (Psa) pressures were recorded continuously. Arterial blood gases (for calculating AaPO2), leukocyte counts, and lymph samples (for prostanoid levels) were collected every 30 min. Eleven animals underwent paired random-order experiments receiving ibuprofen (14 mg/kg) 1 h before human recombinant TNF alpha (10 micrograms/kg), or an identical dose of TNF alpha alone. Within 15 min of initiating TNF alpha, Ppa doubled and remained elevated for 4 h. Ibuprofen prevented the early rise in Ppa after TNF alpha. In the group receiving TNF alpha alone, increases in Ppa were accompanied by a 60% decline in leukocyte count and a 50% increase in AaPo2 within 30 min. Ibuprofen prevented increases in AaPo2, but it had no effect on leukopenia or late increases in lymph flow.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1546845     DOI: 10.1164/ajrccm/145.3.632

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  8 in total

Review 1.  Cytokines induce airway smooth muscle cell hyperresponsiveness to contractile agonists.

Authors:  Y Amrani; R A Panettieri
Journal:  Thorax       Date:  1998-08       Impact factor: 9.139

2.  Effect of tumor necrosis factor receptor binding protein on cell infiltration induced by lipopolysaccharide and Sephadex beads in guinea pig lung.

Authors:  D M Conroy; J N Francischi; P Sirois
Journal:  Inflammation       Date:  1995-04       Impact factor: 4.092

3.  Tumor necrosis factor-alpha-induced inhibition of phosphatidylcholine synthesis by human type II pneumocytes is partially mediated by prostaglandins.

Authors:  J Arias-Díaz; E Vara; C García; J L Balibrea
Journal:  J Clin Invest       Date:  1994-07       Impact factor: 14.808

4.  Cytokine-mediated induction of cyclo-oxygenase-2 by activation of tyrosine kinase in bovine endothelial cells stimulated by bacterial lipopolysaccharide.

Authors:  P Akarasereenont; Y S Bakhle; C Thiemermann; J R Vane
Journal:  Br J Pharmacol       Date:  1995-06       Impact factor: 8.739

5.  Essential role of IFNbeta and CD38 in TNFalpha-induced airway smooth muscle hyper-responsiveness.

Authors:  Deepika Jain; Stefan Keslacy; Omar Tliba; Yang Cao; Sonja Kierstein; Kunjlata Amin; Reynold A Panettieri; Angela Haczku; Yassine Amrani
Journal:  Immunobiology       Date:  2008-01-29       Impact factor: 3.144

6.  Staphylococcal alpha toxin: a study with chronically instrumented awake sheep.

Authors:  S Harshman; P L Lefferts; J R Snapper
Journal:  Infect Immun       Date:  1992-09       Impact factor: 3.441

Review 7.  Understanding cellular mechanisms underlying airway epithelial repair: selecting the most appropriate animal models.

Authors:  B Yahaya
Journal:  ScientificWorldJournal       Date:  2012-09-23

8.  Inhalationally Administered Semifluorinated Alkanes (SFAs) as Drug Carriers in an Experimental Model of Acute Respiratory Distress Syndrome.

Authors:  Matthias Otto; Jörg Krebs; Peter Welker; René Holm; Manfred Thiel; Luciano Gattinoni; Michael Quintel; Charalambos Tsagogiorgas
Journal:  Pharmaceutics       Date:  2021-03-23       Impact factor: 6.321

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.